In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia.

Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.

CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and multiple organ failure. CRS can occur not only in a variety of disease states, but also after organ transplantation, macromolecular drug therapy, and CAR-T product treatment. What is more dangerous is that some patients have a second cytokine storm after they leave the hospital and go home. Eg-009A, developed by Evergreen Therapeutics, Inc., will be used primarily to treat cytokine storms in hospitalized patients with COVID-19. The oral agent EG-009 is mainly used to prevent and treat the second cytokine storm in COVID-19 patients after discharge from the hospital.